IgG4-related disease in the head and neck

Purpose of review To summarize current evidence regarding the pathophysiology, diagnostic criteria, and management of IgG4 disease in the head and neck. Recent findings The anti-CD20 antibody, rituximab is being used increasingly as a primary treatment modality in cases with a definitive diagnosis. Despite the favorable prognosis, it is now recognized that the incidence of cancer development within 3 years of diagnosis is higher than that of the general population. Summary IgG4-related disease is a sclerosing, chronic inflammatory disease, that is benign, and usually occurs in middle-aged to elderly individuals. Definitive diagnosis of IgG4-related disease requires radiological confirmation of enlargement of the affected organ, elevated serum IgG4 levels, and characteristic histopathological findings. Treatment is primarily with systemic corticosteroids or the monoclonal anti-CD20 antibody rituximab, surgical excision, or a combination of treatment modalities. Prognosis is good with complete remission in up to 90% of patients. Correspondence to James Johnston, Department of Surgery, University of Auckland, PO Box 99743, Newmarket, Auckland 1149, New Zealand. Tel: +64 21 1716814; e-mail: jj.johnston@auckland.ac.nz Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2xyEE3p